The European Commission has released its latest medical devices newsletter, outlining a series of important updates under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). These developments reflect the continued effort to strengthen implementation of the regulatory framework while providing additional clarity to manufacturers, notified bodies, and other stakeholders navigating an increasingly structured and data-driven system.
A central focus of the update is the publication and revision of several guidance documents issued by the Medical Device Coordination Group (MDCG). These documents play a critical role in interpreting regulatory requirements and supporting consistent application across Member States. Recent updates include revised guidance on notified bodies, offering further clarification on designation and operational expectations, as well as updates to technical documentation sampling approaches used during conformity assessments. In parallel, the European Medical Device Nomenclature (EMDN) continues to evolve, with new documentation addressing version management and annual revisions. Additional updates also touch on obligations related to supply interruptions, reflecting recent regulatory changes aimed at improving transparency and ensuring continuity of device availability across the EU market.
Progress on the implementation of EUDAMED remains a key highlight. The Commission has published further clarification on the system’s gradual rollout, confirming a phased approach aligned with recent legislative amendments. This staged implementation is intended to allow stakeholders to adapt progressively while ensuring that core functionalities are introduced in a structured manner. With several modules expected to become mandatory in the near future, EUDAMED is set to become a central pillar of regulatory compliance, enhancing traceability, data accessibility, and oversight throughout the product lifecycle.
The newsletter also introduces additional guidance in areas that remain operationally complex for manufacturers. These include clarification on the publication of clinical investigation reports in the absence of a fully functional EUDAMED, as well as developments related to the implementation of Unique Device Identification (UDI) systems for specific product categories. Further attention is given to borderline classification issues, including the regulatory status of certain sterilisation agents, highlighting the ongoing need for clear delineation between medical devices and other regulated product types.
Alongside these regulatory updates, the Commission continues to monitor broader system performance and market dynamics. New data has been shared regarding the availability of medical devices within the EU, as well as the capacity and designation status of notified bodies. These insights are particularly relevant in light of ongoing concerns around certification timelines and potential supply constraints. Supporting materials, including factsheets and stakeholder resources, have also been made available to improve understanding of the regulatory framework across different user groups.
Overall, the latest developments confirm a clear trajectory toward greater harmonisation, transparency, and regulatory oversight within the European medical device landscape. The increasing reliance on MDCG guidance, combined with the progressive implementation of EUDAMED, signals a shift toward a more integrated and data-centric system. For manufacturers, this underscores the importance of maintaining up-to-date regulatory knowledge and ensuring that internal processes, documentation, and registration strategies are aligned with evolving requirements.
Source: https://ec.europa.eu/newsroom/sante/newsletter-archives/74172